Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 versus physician's choice chemotherapy as second-line treatment for recurrent or metastatic esophageal squamous cell carcinoma
CTR20240775Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biokin Pharmaceutical. Started Apr 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20240775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240775.